Prescribe Less, But Better: Optimizing Antibiotic Treatment Duration and Dosing
Background and Context
The rational reduction of antibiotic treatment durations has emerged as a key strategy in the global fight against antimicrobial resistance, a major public health concern. Recent medical literature demonstrates that in uncomplicated, microbiologically confirmed infections with a favorable clinical course, short-course regimens achieve outcomes comparable to traditional prolonged treatment protocols.
Benefits of an Optimized Approach
Shortened antibiotic regimens offer several significant clinical and epidemiological advantages: a reduction in the incidence of adverse drug reactions, decreased selective pressure on resistant bacterial strains, improved treatment adherence, and a reduced environmental impact from antibiotic excretion and dissemination into the ecosystem.
Purpose of This Review
This article provides a concise, up-to-date summary of recommended antibiotic treatment durations in 2025, intended for general practitioners, emergency physicians, internists, and other healthcare professionals involved in antibiotic prescribing. It is based on the most recent French reference guidelines, including those from the Société de Pathologie Infectieuse de Langue Française (SPILF), the Haute Autorité de Santé (HAS), and relevant specialist societies.
The goal is to provide clear, current decision-making benchmarks for rational, effective, and responsible antibiotic prescribing.
1. RESPIRATORY INFECTIONS
Community-Acquired Pneumonia (CAP)
| Clinical Course | Recommended Duration |
|---|
| Clinical improvement by day 3 | 3 days |
| Clinical improvement between day 3 and day 5 | 5 days |
| CAP in the ICU or other complex situations | 7 days |
Aspiration Pneumonia
| Clinical Situation | Recommended Duration |
|---|
| Patient stable by day 5 | 5 days |
| Patient not yet stabilized | 7 days |
Atypical Infections (Whooping Cough / Mycoplasma pneumoniae / Chlamydia pneumoniae)
| Drug | Recommended Duration |
|---|
| Azithromycin 500mg/day | 3 days |
| Clarithromycin (500mg, 2 tabs/day) | 7 days |
Other Lower Respiratory Tract Infections
| Condition | Recommended Duration |
|---|
| Hospital-acquired pneumonia or VAP (excluding empyema, abscess, immunocompromised) | 7 days |
| Acute exacerbation of COPD (GOLD III–IV) | 5 days |
| Purulent pleuritis (empyema) | 14 days (after last drainage) |
2. ENT AND CERVICAL INFECTIONS
Acute Otitis Media
| Population | Recommended Duration |
|---|
| Adult | 5 days |
| Child ≤ 2 years | 10 days |
Group A Streptococcal Pharyngitis (Strep Throat)
| Drug | Recommended Duration |
|---|
| Amoxicillin | 6 days |
| Cefpodoxime (penicillin allergy) | 5 days |
| Clarithromycin (penicillin allergy) | 5 days |
Sinusitis
| Type / Drug | Recommended Duration |
|---|
| Maxillary sinusitis (Amoxicillin 3g/day) | 7 days |
| Maxillary sinusitis, 2nd/3rd-gen. cephalosporin oral (cefuroxime 500mg, 3 tabs/day) | 5 days |
| Maxillary sinusitis, Pristinamycin | 4 days |
| Child | 10 days |
| Non-maxillary sinusitis, amoxicillin-clavulanate | 7 days |
| Non-maxillary sinusitis, 2nd/3rd-gen. cephalosporin oral (cefuroxime 500mg, 3 tabs/day) | 5 days |
| Non-maxillary sinusitis, fluoroquinolone (moxifloxacin 400 mg/day) | 5 days |
Clinical note: Antibiotic withholding may be considered in non-severe cases (children > 2 years)
Cervical Infections
| Condition | Recommended Duration |
|---|
| Lymphadenitis (adult) | 7 days |
| Lymphadenitis (child) | 10 days |
| Peritonsillar, retropharyngeal or parapharyngeal abscess (drained) | 7 days |
| Peritonsillar, retropharyngeal or parapharyngeal abscess (undrained) | 10 days |
| Severe forms (cellulitis, descending necrotizing mediastinitis) | 14 days post-surgery |
3. URINARY TRACT INFECTIONS
Uncomplicated Acute Cystitis (women)
| Drug | Recommended Duration |
|---|
| Fosfomycin trometamol | Single dose |
| Nitrofurantoin (100mg, 3 tabs/day) | 3 days |
| Pivmecillinam | 3 days |
Cystitis at Risk of Complications or Healthcare-Associated
| Drug | Recommended Duration |
|---|
| Fosfomycin trometamol | Day 1 – Day 3 – Day 5 |
| Cotrimoxazole (Bactrim) | 5 days |
| Other agents | 7 days |
Cystitis in Men
| Drug | Recommended Duration |
|---|
| Fosfomycin trometamol | Day 1 – Day 3 – Day 5 |
| Other agents | 7 days |
Acute Pyelonephritis
| Type | Recommended Duration |
|---|
| Uncomplicated (fluoroquinolone) | 7 days |
| At risk of complications or healthcare-associated | 10 days |
| Unfavorable course or abscess | Specialist referral |
Male Genital Infections
| Condition | Recommended Duration |
|---|
| Acute prostatitis (fluoroquinolone) | 14 days |
| Acute epididymitis / orchitis (fluoroquinolone) | 10 days |
4. SEXUALLY TRANSMITTED INFECTIONS
| Condition | Recommended Treatment |
|---|
| Bacterial vaginosis (metronidazole 500 mg twice daily) | 7 days |
| Vulvovaginitis (metronidazole 500 mg twice daily) | 7 days |
| Gonococcal or chlamydial urethritis / cervicitis | Single-dose ceftriaxone + doxycycline 7 days |
| Early syphilis (primary or secondary) | Single-dose benzathine penicillin G |
Pelvic Inflammatory Disease (women)
| Condition | Recommended Treatment |
|---|
| Uncomplicated PID | Single-dose ceftriaxone (1g IM) + doxycycline 10 days (100 mg twice daily) + metronidazole 10 days (500 mg three times daily) |
| Complicated PID | Ceftriaxone (1g IM) until improvement (max 7 days) + doxycycline 14 days (100 mg twice daily) + metronidazole 14 days (500 mg three times daily) |
5. SKIN AND SOFT TISSUE INFECTIONS
| Condition | Recommended Duration |
|---|
| Simple furuncle (boil) | No oral antibiotic |
| Simple impetigo | No oral antibiotic |
| Contaminated wound | 5 days |
| Drained abscess | 5 days |
| Animal bite | 5 days |
| Non-necrotizing bacterial cellulitis, severe impetigo, furunculosis | 7 days |
6. BONE AND JOINT INFECTIONS
Septic Arthritis
| Pathogen | Recommended Duration |
|---|
| S. aureus, Enterobacteriaceae | 6 weeks |
| Streptococci | 4 weeks |
| N. gonorrhoeae | 7 days |
Other Bone and Joint Infections
| Condition | Recommended Duration |
|---|
| Spondylodiscitis (without hardware or with hardware replacement) | 6 weeks |
| Septic bursitis | 14 days |
7. DIABETIC FOOT
| Clinical Situation | Recommended Duration |
|---|
| Osteitis without amputation | 6 weeks |
| Osteitis at the amputation margin | 3 weeks |
| Complete amputation with no associated infection | 5 days |
| Amputation with skin infection | 7 days (up to 14 days if slow clinical response) |
8. BACTEREMIA AND DEVICE-RELATED INFECTIONS
Uncomplicated Bacteremia
| Pathogen | Recommended Duration |
|---|
| Enterobacteriaceae, Streptococci, Enterococci | 7 days |
| Staphylococcus aureus, S. lugdunensis | 14 days |
Catheter-Related Bloodstream Infections (after removal + negative blood cultures)
| Pathogen | Recommended Duration |
|---|
| Coagulase-negative staphylococci | 3 days |
| Other bacteria | 7 days |
| S. aureus | 14 days |
| Candida spp. | 14 days |
| Septic thrombophlebitis | 21 days |
Endocarditis
| Pathogen | Recommended Duration |
|---|
| Streptococci | 4 to 6 weeks (depending on valve involvement) |
| Enterococci | 6 weeks (depending on valve involvement) |
| S. aureus | 4 to 6 weeks (depending on valve involvement) |
9. INFECTIONS DIGESTIVES
| Pathologie | Durée recommandée |
|---|
| Diarrhée aiguë du voyageur | Azithromycine dose unique |
| Diarrhée à Shigella/Campylobacter (enfant) | 3 jours |
| Diarrhée à Yersinia (enfant) | 5 jours |
| Diarrhée à Salmonella (enfant) | 3 ou 5 jours selon indication et terrain |
| Infection à Clostridium difficile | 10 jours |
| Appendicite non opérée non perforée | 7 jours |
| Péritonite localisée | 3 jours |
| Péritonite généralisée | 4 jours |
| Diverticulite non compliquée | Pas d'antibiotique (suivi) |
| Diverticulite compliquée/abcès | 3 jours si drainé / 7 jours sinon |
| Abcès hépatique drainé | 3 semaines |
| Abcès hépatique non drainé | ≥ 28 jours |
Éradication de l'Helicobacter pylori (10 jours)
Schéma de première intention :
| Médicament | Posologie |
|---|
| IPP (oméprazole ou équivalent) | 40 mg × 2/jour |
| Amoxicilline | 2 g en 2 prises/jour |
| Clarithromycine | 1 g en 2 prises/jour |
| Métronidazole | 1 g en 2 prises/jour |
Schéma alternatif (quadrithérapie au bismuth /Pylera) :
| Médicament | Posologie |
|---|
| IPP (oméprazole ou équivalent) | 40 mg × 2/jour |
| PYLERA (3 gélules 4cpr/j) | |
| Bismuth | 1680 mg en 4 prises/jour |
| Tétracycline | 1500 mg en 4 prises/jour |
| Métronidazole | 1500 mg en 4 prises/jour |
MESSAGES CLÉS POUR LA PRATIQUE
Réévaluation systématique
Réévaluer toute antibiothérapie à 48–72 heures
Adaptation clinique
Adapter la durée à l'évolution clinique et non à l'habitude
Qualité des soins
Les durées courtes sont un indicateur de qualité des soins
Avis spécialisé
En cas de doute ou de situation complexe : avis spécialisé
Bibliographie
SPILF – Société de Pathologie Infectieuse de Langue Française
Recommandations issues du document Info-antibio n°107 – Décembre 2025, élaboré par le groupe GPIP, publié dans Médecine et Maladies Infectieuses – Formation.
CBIP (Centre Belge d'Information Pharmacothérapeutique). Disponible sur : https://www.cbip.be/fr/
VIDAL. VIDAL - La base de données en ligne des prescripteurs libéraux. Paris: VIDAL; 2025. Disponible sur : https://www.vidal.fr/
